|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||21.97 - 24.24|
|52-week range||21.97 - 24.24|
|Beta (5Y monthly)||0.13|
|PE ratio (TTM)||284.15|
|Earnings date||02 May 2022 - 06 May 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
One thing we could say about the analysts on AnaptysBio, Inc. ( NASDAQ:ANAB ) - they aren't optimistic, having just...
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.